Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0178874 (tumor progression)
 40,807 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Thirty patients with metastatic renal cell cancer were treated by renal infarction, followed by delayed nephrectomy. All cases were collected over an eighteen-month period, with a minimum follow-up of one year. There were no complete remissions and only one partial remission, which lasted twenty-one months before progression of disease. Three patients had stable disease for at least six months, but eventually all patients showed evidence of progression. After tumor progression was documented patients were treated with intramuscular medroxyprogesterone acetate (Depo-Provera) 800 mg per week. No patient responded to this therapy. Overall, a 28 per cent one-year survival and a seven-month median survival were realized, which is similar to other series in which no therapy or palliative nephrectomy was performed. We conclude that infarction and nephrectomy is not an effective modality in the treatment of metastatic renal cell carcinoma. In addition, medroxyprogesterone was not shown to be significantly active against renal cancer in this study.
 ...
PMID:Infarction-nephrectomy for metastatic renal carcinoma. Southwest oncology group study. 315 42

This is the report of results from a phase 2 trial of high-dose progestin therapy for treatment of ovarian cancer. 19 women received 1000 mg of Depo Provera (medroxyprogesterone acetate) weekly by intramuscular injection for at least 8 weeks and longer if there was no evidence of tumor progression. None of the women in the study was responding any longer to surgery, radiation therapy, or conventional cytotoxic chemotherapy. Response was measured as: 1) regression if there was at least a 50% decrease in the area of measurable lesion; or 2) disease progression as at least a 25% increase over the original measurements or the appearance of new lesions. Based on these criteria, there were no responses in the 19 women. Only 1 patient remained stable (3 months). Median survival time was 2 months with 75% of the patients dying within 4 months. 1 patient suffered severe vomiting and another experienced bleeding; there was no other toxicity. It is concluded that progestin therapy does not have a beneficial effect and its use in ovarian cancer patients should be limited to those with endometrioid histology.
 ...
PMID:Progestin therapy for advanced ovarian cancer: a phase II Eastern Cooperative Oncology Group trial. 727 26